Leerink Swann Maintains an 'Outperform' on Medivation (MDVN); Number of Advantages Based on Labeling
Tweet Send to a FriendGet Alerts MDVN Hot Sheet
Price: $47.53 -1.57%
Rating Summary:
18 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
18 Buy, 3 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade MDVN Now!
Leerink Swann maintains an 'Outperform' on Medivation (NASDAQ: MDVN) price target of $122.00.
Analyst, Howard Liang, said, "Based on our detailed comparison of product labels, we believe that the Xtandi label has a number of advantages over Zytiga (NYSE: JNJ) including lack of food effect and monitoring requirements, in addition to lack of need for steroid coadministration. Although there is a small risk of seizure, we believe current data suggest an efficacy advantage for Xtandi that would eventually be a more important determinant."
For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.
Shares of Medivation closed at $104.86 yesterday, with a 52 week range of $15.49-$105.00.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Howard Liang, said, "Based on our detailed comparison of product labels, we believe that the Xtandi label has a number of advantages over Zytiga (NYSE: JNJ) including lack of food effect and monitoring requirements, in addition to lack of need for steroid coadministration. Although there is a small risk of seizure, we believe current data suggest an efficacy advantage for Xtandi that would eventually be a more important determinant."
For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.
Shares of Medivation closed at $104.86 yesterday, with a 52 week range of $15.49-$105.00.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- UPDATE: Leerink Swann Upgrades Bristol-Myers Squibb Co. (BMY) to Outperform
- Topeka Capital Starts Laredo Petroleum (LPI) at Buy, Assets 'Undervalued'
Create E-mail Alert Related Categories
Analyst Comments, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
